Developer docs
API playgroundTry for free, no card

Search company profiles

Molecule.one

Full company profile

uuid0000ocg

Namestring
Molecule.one
Legal namestring
Molecule One Inc.
Websiteurl
molecule.one
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarsaw, Poland
HQ citystring
Warsaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI retrosynthesis planning, synthesis design software, high-throughput experimentation, autonomous chemistry discovery, computational drug discovery
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Software Publishers5132
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Integrated Systems Design7373
Product category
AI Drug Discovery Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Maria™ AI Platform Licensing
TypeLicensing Royalties
Description

Licensing the Maria™ AI platform to CDMOs, Pharma, Biotechs and Frontier AI companies for deep autonomous research chemistry projects. The platform discovers and delivers synthetic pathways, customized compound spaces, and hit series with confirmed activity.

molecule.one
2Research Partnerships
TypeProfessional Services
Description

Strategic collaborations with pharmaceutical and biotech companies for synthesis planning, compound discovery, and AI-driven drug development. Includes delivery of efficient synthetic pathways and experimentally validated outputs.

molecule.one
3Synthesis Planning Software
TypeSubscription Recurring
Description

Commercial software based on deep learning models for chemical synthesis planning, first launched commercially in 2019.

molecule.one
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Maria AI
Description

Frontier chemistry models combined in an agentic framework to solve chemical problems and discover new chemistry

molecule.one
+2 more records
Core offering1 text field

Molecule.one develops the Maria™ AI platform, which combines frontier chemistry models in an agentic framework, a proprietary microliter-scale high-throughput experimentation laboratory, and a large proprietary reaction dataset to enable near-autonomous chemistry research. The company licenses this platform to pharmaceutical, biotechnology, CDMO, and frontier AI customers for synthesis planning, customized compound-space design, and experimentally validated hit discovery. It also delivers multi-year research partnership engagements that produce synthetic pathways and validated compound outputs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Mean yield improvement from 16.6% to 25.2% in Chan-Lam coupling for primary sulfonamides using AI-identified TEMPO additive
+5 more records
Product overview1 text field

Molecule.one offers the Maria™ platform, a unified system that unites AI, Lab, and Data to power near-autonomous chemistry research. The platform consists of three integrated components: Maria AI (frontier chemistry models in an agentic framework), Maria Lab (micro-liter scale HTE laboratory operating at 12,000 reactions per week), and Maria Data (proprietary dataset of 300,000+ reactions). The Retrosynthesis Platform and RetroTrim ensemble system provide trustworthy AI-driven synthesis planning that has won the $1M Standard Industries AI Challenge. The system achieves a closed loop where AI proposes experiments, the lab runs them at scale, and resulting data improves the AI models.

Product and service2 records
1Maria™ AI Platform
CategoryAI-driven synthesis planning platform
Description

Unified AI platform combining frontier chemistry models in an agentic framework (Maria AI), a proprietary microliter-scale high-throughput experimentation lab (Maria Lab, 12,000+ reactions per week), and a proprietary dataset of 300,000+ reactions with 100x wider building-block diversity (Maria Data). Licensed to pharmaceutical, biotech, CDMO, and frontier AI customers for synthesis planning, customized compound space design, and experimentally validated hit discovery.

2Retrosynthesis Platform
CategoryRetrosynthesis and synthesis planning software
Description

AI-powered synthesis planning tool that uses deep neural networks, including the RetroTrim ensemble (Reaction Prior, GraphScore, Retrieval Score), to generate and evaluate creative synthetic routes for target molecules and eliminate hallucinations in retrosynthesis. Delivered to enterprise customers and used internally for autonomous chemistry discovery including Chan-Lam coupling improvement with OpenAI.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Connected GPT-5.4 model to Molecule.one's Maria AI system and high-throughput laboratory to autonomously improve Chan-Lam coupling reactions. AI identified TEMPO as additive improving mean yields from 16.6% to 25.2%. Ran 10,080 reactions across two cycles over three months - first chemistry discovery where AI proposed novel experiment that held up in lab.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

Multi-year strategic agreement to accelerate drug development and enhance chemical manufacturing, focusing on synthesizing peptide building blocks using Molecule.one's AI platform. Result of winning the $1M Standard Industries AI Challenge.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-12
Description

Won $1 million AI Challenge organized by Standard Industries and W.R. Grace for advancements in AI-assisted molecular synthesis and retrosynthesis processes.

4CAS (Chemical Abstracts Service)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-11
Description

Strategic collaboration to accelerate drug discovery and develop the world's best platform for Synthetic Accessibility Scoring. CAS provides access to world's largest database of chemical reactions.

molecule.one
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecule.one

AI Drug Discovery Softwaremolecule.one

Molecule.one firmographics

Firmographics
Name
Molecule.one
Legal name
Molecule One Inc.
Website
https://molecule.one
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where Molecule.one is headquartered

Location

Headquarters

HQ city
Warsaw
HQ country
Poland
HQ region
Europe

Offices3 records

Markets served

Molecule.one business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Maria™ AI Platform Licensing: Licensing the Maria™ AI platform to CDMOs, Pharma, Biotechs and Frontier AI companies for deep autonomous research chemistry projects. The platform discovers and delivers synthetic pathways, customized compound spaces, and hit series with confirmed activity.
  2. Research Partnerships: Strategic collaborations with pharmaceutical and biotech companies for synthesis planning, compound discovery, and AI-driven drug development. Includes delivery of efficient synthetic pathways and experimentally validated outputs.
  3. Synthesis Planning Software: Commercial software based on deep learning models for chemical synthesis planning, first launched commercially in 2019.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Molecule.one product offering

Product offering

Core offering

Molecule.one develops the Maria™ AI platform, which combines frontier chemistry models in an agentic framework, a proprietary microliter-scale high-throughput experimentation laboratory, and a large proprietary reaction dataset to enable near-autonomous chemistry research. The company licenses this platform to pharmaceutical, biotechnology, CDMO, and frontier AI customers for synthesis planning, customized compound-space design, and experimentally validated hit discovery. It also delivers multi-year research partnership engagements that produce synthetic pathways and validated compound outputs.

Product overview

Molecule.one offers the Maria™ platform, a unified system that unites AI, Lab, and Data to power near-autonomous chemistry research. The platform consists of three integrated components: Maria AI (frontier chemistry models in an agentic framework), Maria Lab (micro-liter scale HTE laboratory operating at 12,000 reactions per week), and Maria Data (proprietary dataset of 300,000+ reactions). The Retrosynthesis Platform and RetroTrim ensemble system provide trustworthy AI-driven synthesis planning that has won the $1M Standard Industries AI Challenge. The system achieves a closed loop where AI proposes experiments, the lab runs them at scale, and resulting data improves the AI models.

Differentiator

Problem solved

Functional benefit

Brands

  • Maria AI: Frontier chemistry models combined in an agentic framework to solve chemical problems and discover new chemistry
  • Maria Lab
  • Maria Data

Products and services

  • Maria™ AI Platform Unified AI platform combining frontier chemistry models in an agentic framework (Maria AI), a proprietary microliter-scale high-throughput experimentation lab (Maria Lab, 12,000+ reactions per week), and a proprietary dataset of 300,000+ reactions with 100x wider building-block diversity (Maria Data). Licensed to pharmaceutical, biotech, CDMO, and frontier AI customers for synthesis planning, customized compound space design, and experimentally validated hit discovery.
  • Retrosynthesis Platform AI-powered synthesis planning tool that uses deep neural networks, including the RetroTrim ensemble (Reaction Prior, GraphScore, Retrieval Score), to generate and evaluate creative synthetic routes for target molecules and eliminate hallucinations in retrosynthesis. Delivered to enterprise customers and used internally for autonomous chemistry discovery including Chan-Lam coupling improvement with OpenAI.

Quantifiable outcome

  • Mean yield improvement from 16.6% to 25.2% in Chan-Lam coupling for primary sulfonamides using AI-identified TEMPO additive
  • +5 more outcomes

Companies that use Molecule.one

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Molecule.one technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Molecule.one partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • OpenAIflagshipStrategic or Co-development Partner · 17 June 2026Connected GPT-5.4 model to Molecule.one's Maria AI system and high-throughput laboratory to autonomously improve Chan-Lam coupling reactions. AI identified TEMPO as additive improving mean yields from 16.6% to 25.2%. Ran 10,080 reactions across two cycles over three months - first chemistry discovery where AI proposed novel experiment that held up in lab.
  • W. R. Grace & Co.flagshipStrategic or Co-development Partner · 8 December 2025Multi-year strategic agreement to accelerate drug development and enhance chemical manufacturing, focusing on synthesizing peptide building blocks using Molecule.one's AI platform. Result of winning the $1M Standard Industries AI Challenge.
  • Standard IndustriesflagshipStrategic or Co-development Partner · 12 June 2025Won $1 million AI Challenge organized by Standard Industries and W.R. Grace for advancements in AI-assisted molecular synthesis and retrosynthesis processes.
  • CAS (Chemical Abstracts Service)coreStrategic or Co-development Partner · 11 August 2023Strategic collaboration to accelerate drug discovery and develop the world's best platform for Synthetic Accessibility Scoring. CAS provides access to world's largest database of chemical reactions.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Molecule.one competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Molecule.one social profiles

Digital presence

Molecule.one financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecule.one leadership team

Management profile

Number of profiles

Profiles12 records

Molecule.one funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecule.one M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecule.one

What does Molecule.one do?

Molecule.one develops the Maria™ AI platform, which combines frontier chemistry models in an agentic framework, a proprietary microliter-scale high-throughput experimentation laboratory, and a large proprietary reaction dataset to enable near-autonomous chemistry research. The company licenses this platform to pharmaceutical, biotechnology, CDMO, and frontier AI customers for synthesis planning, customized compound-space design, and experimentally validated hit discovery. It also delivers multi-year research partnership engagements that produce synthetic pathways and validated compound outputs.

Is Molecule.one a public or private company?

Molecule.one is a private company. It is classified as venture growth investor backed and is currently operating.

When was Molecule.one founded?

Molecule.one was founded in 2019. It employs 11 to 50 people.

Where is Molecule.one based?

Molecule.one is headquartered in Warsaw, Poland, in the Europe region.

How does Molecule.one make money?

Three revenue lines are on record. Maria™ AI Platform Licensing is the primary driver. The others are research Partnerships and synthesis Planning Software.

Does Molecule.one have an API?

No public API is recorded for Molecule.one.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ForbesWhen AI Becomes People: And The Role Of ScienceAt a Next Endeavor event, panelists discussed AI scientists and physical AI systems like Molecule.one's Maria, which optimized the Chan-Lam coupling reaction with GPT-5.4. Maria ran 10,080 micro-liter reactions, improving yields for 88% of boronic acids and 83% of sulfonamides, raising mean yield from 16.6% to 25.2%.RdworldonlineOpenAI and Molecule.one report a near-autonomous AI chemist that improved a stubborn coupling reactionOpenAI and Molecule.one announced a system pairing GPT-5.4 with Maria and an automated lab to improve primary sulfonamide Chan-Lam coupling. Yields rose from 16.6% to 25.2% across 10,080 reactions, with 37.5% of reactions clearing 30% yield. The preprint notes TEMPOL maintained comparable performance.Tech TimesAI Drug Discovery Chemistry Hits Wet Lab: GPT-5.4 Boosts Chan-Lam Yields in 10,080 ReactionsOpenAI's GPT-5.4, with Molecule.one, ran 10,080 reactions and found adding TEMPO improved Chan-Lam coupling yields for primary sulfonamides. Yields rose from 16.6% to 25.2%, and reactions clearing 30% yield increased from 15.6% to 37.5%. Human chemists validated the result at bench scale.OpenAIA near-autonomous AI chemist improves a challenging reaction in medicinal chemistryOpenAI partnered with Molecule.one to connect GPT-5.4 with Maria, an agentic chemistry AI integrated with a high-throughput laboratory, for a near-autonomous medicinal chemistry research project that ran 10,080 reactions over three months. The system identified TEMPO as an effective additive for Chan-Lam coupling of primary sulfonamides, improving mean yield from 16.6% to 25.2% and increasing the share of reactions above 30% yield from 15.6% to 37.5%, with results validated at bench scale by human chemists and reviewed by four external experts. This demonstrates a collaborative AI-human workflow where the model proposed hypotheses and designed experiments while humans provided steering, corrections, and validation, marking a concrete step toward AI becoming a scientific research partner.OpenAIA near-autonomous AI chemist improves a challenging reaction in medicinal chemistryOpenAI connected its GPT-5.4 model to Molecule.one's Maria AI system and high-throughput laboratory to autonomously improve Chan-Lam coupling reactions for primary sulfonamides, a historically low-yield reaction in medicinal chemistry. The AI identified TEMPO as an additive that improved mean yields from 16.6% to 25.2% and increased the share of reactions exceeding 30% yield from 15.6% to 37.5%, running 10,080 reactions across two cycles over three months, with bench-scale validation by human chemists confirming the results.AETOSWireCAS and Molecule.one Announce a Strategic Collaboration to Accelerate Drug DiscoveryCAS and Molecule.one announced a strategic collaboration to develop AI-based chemical synthesis planning tools for drug discovery. The first offering, M1 RetroScore powered by CAS, will launch August 14 and uses CAS's chemical reactions content to predict synthetic accessibility. The collaboration aims to accelerate early-stage drug discovery by improving retrosynthesis capabilities.PR NewswireGrace and Molecule.one to Transform Peptide Building Block Synthesis with AI and AutomationW. R. Grace & Co. and Molecule.one have entered a multi-year strategic agreement to utilize AI and automation for the synthesis of peptide building blocks, addressing supply chain bottlenecks in therapeutic manufacturing. The collaboration aims to accelerate drug development timelines and strengthen U.S. manufacturing capabilities for compounds essential to treatments like GLP-1 drugs.GraceGrace and Molecule.one to Transform Peptide Building Block Synthesis with AI and AutomationW. R. Grace & Co. and Molecule.one announced a multi-year strategic agreement to utilize AI and automation for the synthesis of peptide building blocks essential for pharmaceutical manufacturing. The collaboration aims to address supply chain bottlenecks in metabolic-disease treatments, such as GLP-1 drugs, by accelerating development timelines and scaling production capabilities. This partnership leverages Molecule.one's MARIA platform to optimize chemical processes and enhance U.S. manufacturing efficiency.GraceStandard Industries Announces Molecule.one as Winner of $1 Million AI ChallengeStandard Industries and its operating company W. R. Grace awarded Molecule.one $1 million for winning the Chemical Innovation Challenge focused on AI-assisted molecular synthesis. The prize recognizes Molecule.one's deep learning platform designed to accelerate the development and production of pharmaceuticals by optimizing chemical retrosynthesis processes.GraceMolecule.one Wins Standard Industries Chemical Innovation ChallengeStandard Industries and Grace announced Molecule.one as the winner of the Standard Industries Chemical Innovation Challenge, awarding the team a $1 million prize for its AI platform. The winning platform demonstrated superior accuracy in generating chemically feasible synthetic routes for complex molecules, effectively mitigating the hallucination issues common in other AI models. This collaboration aims to accelerate pharmaceutical development by optimizing retrosynthesis processes for drugs such as cardiovascular and oncology treatments.